相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Therapeutic potential of CAR T cell in malignancies: A scoping review
Ali Zarezadeh Mehrabadi et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
Do-Youn Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Heinz-Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau et al.
LANCET ONCOLOGY (2022)
Potential Application of Exosomes in Vaccine Development and Delivery
Md Nurul Huda et al.
PHARMACEUTICAL RESEARCH (2022)
Novel Cellular Therapies for Hepatocellular Carcinoma
Harriet Roddy et al.
CANCERS (2022)
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights
Christo Kole et al.
CANCER MANAGEMENT AND RESEARCH (2022)
The next wave of cellular immunotherapies in pancreatic cancer
Dannel Yeo et al.
MOLECULAR THERAPY-ONCOLYTICS (2022)
An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer
Maryum Nisar et al.
FRONTIERS IN ONCOLOGY (2022)
An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma
Eleni-Myrto Trifylli et al.
LIFE-BASEL (2022)
Trial in progress: A randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC).
John Davelaar et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma
Jiaojiao Guo et al.
CANCER GENE THERAPY (2021)
Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer
Zelin Hou et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
Current immunotherapy in gastrointestinal malignancies A Review
Dushyant Singh Dahiya et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
Philippe Rochigneux et al.
CANCERS (2021)
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Karthik Dhatchinamoorthy et al.
FRONTIERS IN IMMUNOLOGY (2021)
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
Zoe C. Schmiechen et al.
FRONTIERS IN IMMUNOLOGY (2021)
Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer
Jill P. Smith et al.
FRONTIERS IN ONCOLOGY (2021)
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo et al.
FRONTIERS IN ONCOLOGY (2021)
Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy
Evangelos Koustas et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors
Alison P. Klein
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
The Implication of Autophagy in Gastric Cancer Progression
Evangelos Koustas et al.
LIFE-BASEL (2021)
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
ONCOLOGIST (2021)
The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
Oraianthi Fiste et al.
VACCINES (2021)
Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines
Ali Azadi et al.
BIOLOGICAL PROCEDURES ONLINE (2021)
Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis
Hui Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
Osama E. Rahma et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
Gang Jin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren et al.
LANCET ONCOLOGY (2021)
Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
Ding-Kang Wang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
Maria Gutierrez-Larranaga et al.
LIVER CANCER (2021)
Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Junhee Pyo et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
Elisa Grassi et al.
FRONTIERS IN ONCOLOGY (2021)
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Arndt Vogel et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Cancer Vaccines: Promising Therapeutics or an Unattainable Dream
Howard Donninger et al.
VACCINES (2021)
Prognostic role of tumour-infiltrating lymphocytes assessed by H&E-stained section in gastric cancer: a systematic review and meta-analysis
Chunfang Tian et al.
BMJ OPEN (2021)
Update of early phase clinical trials in cancer immunotherapy
Dae Ho Lee
BMB REPORTS (2021)
Current status of immunotherapy for advanced gastric cancer
Akihito Kawazoe et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)
CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety
Huali Li et al.
JOURNAL OF CANCER (2021)
The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
Ryota Tamura et al.
MEDICAL ONCOLOGY (2020)
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Suneel D. Kamath et al.
ONCOLOGIST (2020)
Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory
Wenhao Luo et al.
CANCER CELL INTERNATIONAL (2020)
Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway (vol 74, pg 2351, 2019)
Chao Liu et al.
CELL DEATH AND DIFFERENTIATION (2020)
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Li-Tzong Chen et al.
GASTRIC CANCER (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Gut microbiome in HCC - Mechanisms, diagnosis and therapy
Robert F. Schwabe et al.
JOURNAL OF HEPATOLOGY (2020)
Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis
Gabor Lendvai et al.
PATHOLOGY & ONCOLOGY RESEARCH (2020)
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features
Xiaoqiao Liu et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Cancer immunotherapy: Pros, cons and beyond
Shuzhen Tan et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
The Changing Epidemiology of Hepatocellular Carcinoma : Experience of a Single Center
Lydia Giannitrapani et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Cancer vaccines: Targeting KRAS-driven cancers
Ying Zhang et al.
EXPERT REVIEW OF VACCINES (2020)
Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam?
Yuwei Li et al.
CANCER MEDICINE (2020)
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
Sarina A. Piha-Paul et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
Evangelos Koustas et al.
BIOMOLECULES (2020)
The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis
Adile Orhan et al.
EUROPEAN JOURNAL OF CANCER (2020)
Immunotherapy for pancreatic cancer: A 2020 update
Dimitrios Schizas et al.
CANCER TREATMENT REVIEWS (2020)
Myeloid-Derived Suppressor Cells in Colorectal Cancer
Izabela Sieminska et al.
FRONTIERS IN IMMUNOLOGY (2020)
CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer
Dominika Bebnowska et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models
Evangelos Koustas et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy
Shunda Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Adham S. Bear et al.
CANCER CELL (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Mechanisms of immune escape in the cancer immune cycle
Sha Tang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
IDO Expression in Cancer: Different Compartment, Different Functionality?
Annabel Meireson et al.
FRONTIERS IN IMMUNOLOGY (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs)
Shuting Han et al.
CANCERS (2020)
Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma
Clifford Akateh et al.
WORLD JOURNAL OF HEPATOLOGY (2020)
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
Daniele Biasci et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
Lawrence G. Lum et al.
ONCOIMMUNOLOGY (2020)
TIM3 comes of age as an inhibitory receptor
Yochai Wolf et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Jung-Ho Kim et al.
IMMUNE NETWORK (2020)
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions
Sho Sasaki et al.
GASTRIC CANCER (2019)
Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
Cong Chen et al.
ONCOIMMUNOLOGY (2019)
Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer
Aesha I. Ali et al.
FRONTIERS IN ONCOLOGY (2019)
Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Yoshihiro Ohue et al.
CANCER SCIENCE (2019)
Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
Josep M. Llovet et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety
Steven S. Raman et al.
IMMUNOTHERAPY (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Immunotherapy for hepatocellular carcinoma: Current and future
Michael P. Johnston et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Complementing the Cancer-Immunity Cycle
Ruben Pio et al.
FRONTIERS IN IMMUNOLOGY (2019)
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
M. Moehler et al.
ONCOIMMUNOLOGY (2019)
Immunotherapy in advanced gastric cancer, is it the future?
C. Coutzac et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Vaccines for colorectal cancer: an update
Mostafa Sarvizadeh et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
Divya Thomas et al.
MOLECULAR CANCER (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Akram Pourshams et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Inflammation and pancreatic cancer: An updated review
Kamleshsingh Shadhu et al.
SAUDI JOURNAL OF GASTROENTEROLOGY (2019)
Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer
Dachuan Zhang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
Jesus Rodriguez-Pascual et al.
CANCER DRUG RESISTANCE (2019)
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Elucidating the link between collagen and pancreatic cancer: what's next?
Shin Hamada et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.
Luigi Buonaguro et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics
Karie Runcie et al.
MOLECULAR MEDICINE (2018)
The Potential of CAR T Cell Therapy in Pancreatic Cancer
Mehmet Akce et al.
FRONTIERS IN IMMUNOLOGY (2018)
The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status
Evangelos Koustas et al.
PLOS ONE (2018)
Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens
Sandra Wagner et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
Krupa Naran et al.
FRONTIERS IN MICROBIOLOGY (2018)
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Kate Young et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy
Shoichi Hazama et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY (2018)
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
M. Hidalgo et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients
Akihito Kawazoe et al.
GASTRIC CANCER (2017)
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
Elizabeth D. Thompson et al.
GUT (2017)
The colorectal cancer immune microenvironment and approach to immunotherapies
Minoru Koi et al.
FUTURE ONCOLOGY (2017)
Targeting the Tumor Stroma: the Biology and Clinical Development of Pegylated Recombinant Human Hyaluronidase (PEGPH20)
Kit Man Wong et al.
CURRENT ONCOLOGY REPORTS (2017)
Molecular classifications of gastric cancers: Novel insights and possible future applications
Silvio Ken Garattini et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Lihu Gu et al.
PLOS ONE (2017)
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
Omid Hamid et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer
Evangelos Koustas et al.
CANCER LETTERS (2017)
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Molecular evolution of colorectal cancer: from multistep carcinogenesis to the big bang
Adriana Amaro et al.
CANCER AND METASTASIS REVIEWS (2016)
Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma
Christopher C. DuFort et al.
GASTROENTEROLOGY (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells
Luana Lugini et al.
ONCOTARGET (2016)
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
Christine Boeger et al.
ONCOTARGET (2016)
TRUCKs: the fourth generation of CARs
Markus Chmielewski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
M. Aglietta et al.
ANNALS OF ONCOLOGY (2014)
Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects
Yukai He et al.
IMMUNOTHERAPY (2014)
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater et al.
JOURNAL OF HEPATOLOGY (2014)
Pancreatic cancer, treatment options, and GI-4000
Marion L. Hartley et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Vaccines versus immunotherapy: Overview of approaches in deciding between options
Angus G. Dalgleish
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance
Douglas T. Fearon
CANCER IMMUNOLOGY RESEARCH (2014)
Oncolytic viral therapy for pancreatic cancer: current research and future directions
Justin W. Ady et al.
ONCOLYTIC VIROTHERAPY (2014)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside Translation
Vincenzo Corbo et al.
CURRENT DRUG TARGETS (2012)
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer
Toru Masuzawa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Oncolytic vaccinia virus for the treatment of cancer
Kilian Guse et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Potential targets for pancreatic cancer immunotherapeutics
Lindzy F. Dodson et al.
IMMUNOTHERAPY (2011)
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
Jeong Heo et al.
MOLECULAR THERAPY (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
Milind M. Javle et al.
BMC CANCER (2010)
BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome
Z. Saridaki et al.
BRITISH JOURNAL OF CANCER (2010)
MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models
Jung-ah Cho et al.
CANCER LETTERS (2009)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer
Howard L. Kaufman et al.
CLINICAL CANCER RESEARCH (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: The GC4 study
JA Ajani et al.
CANCER (2006)
Allergies and the risk of pancreatic cancer: A meta-analysis with review of epidemiology and biological mechanisms
S Gandini et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)